Public Policy Letters, Statements, Legal Briefs, & Other Responses
← Back to all Letters & Statements
-
ACMG Responds to FDA’s Approval for DTC Testing for Three BRCA Gene Mutations
-
ACMG Comments to CMS on Proposed NCD for Coverage of NGS for Medicare Beneficiaries with Advanced Cancer (CAG-00450N)